TITLE

Oral Antiplatelet Therapy for the Management of Acute Coronary Syndromes: Defining the Role of Prasugrel

AUTHOR(S)
Devabhakthuni, Sandeep; Seybert, Amy L.
PUB. DATE
February 2011
SOURCE
Critical Care Nurse;Feb2011, Vol. 31 Issue 1, p51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antiplatelet therapy is important in the prevention of thrombosis, a significant cause of morbidity and mortality that is associated with acute coronary syndrome. Current evidence supports the general acceptance of aspirin and clopidogrel as the standard of care for the management of all patients experiencing an acute coronary syndrome with or without percutaneous coronary intervention. Thienopyridine antiplatelet agents such as clopidogrel, when used alone and in combination with aspirin, are effective in preventing myocardial infarction and death. Prasugrel, a potent antiplatelet agent that was recently approved by the Food and Drug Administration, may have some advantages over other antiplatelet agents, owing to its rapid onset of action, higher degree of platelet inhibition, and decreased interpatient variability in pharmacokinetics and pharmacodynamics as compared with clopidogrel. However, further studies are required to assess the potential for increased bleeding in high-risk patients.
ACCESSION #
57678960

 

Related Articles

  • FDA Actions: New Oral Antiplatelet Agent.  // Critical Care Alert;Sep2009 Pharmacology, p1 

    The article reports that prasugrel, an oral antiplatelet agent in preventing thrombosis in patients with acute coronary syndrome, has been approved by the Food and Drug Administration (FDA).

  • Diabetes -- A Benefit from Targeted Therapy with Prasugrel in ACS. Abrama, Jonathan // Clinical Cardiology Alert;Dec2008, Vol. 27 Issue 12, p89 

    The article discusses a study with regard to prasugrel, a third-generation oral thienopyridine. According to the study, prasugrel can provide platelet inhibitions in acute coronary syndromes (ACS). It notes that reduction in ischemic events can be reduced through intrusive and consistent...

  • Prasugrel. Duggan, Sean T.; Keating, Gillian M. // Drugs;2009, Vol. 69 Issue 12, p1707 

    Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina...

  • FDA Actions: New Oral Antiplatelet Agent.  // Neurology Alert;Sep2009 Pharmacology Watch, p1 

    This articles reports on U.S. Food and Drug Administration's (FDA) approval of prasugrel, an oral antiplatelet agent to prevent thrombosis in patients with acute coronary syndrome and who are to be managed by angioplasty. It also advises not to use the drug in patients with history of stroke and...

  • Genotype-guided antiplatelet therapy dominant in the US.  // PharmacoEconomics & Outcomes News;3/31/2012, Issue 650, p3 

    The article reports on a study which found that genotype-guided antiplatelet therapy with either clopidogrel or prasugrel is more cost effective than prasugrel or clopidogrel used without genetic testing for the treatment of patients with acute coronary syndromes scheduled to undergo...

  • Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Davis, Estella M.; Knezevich, Jon T.; Teply, Robyn M. // Clinical Pharmacology;2013, Vol. 5, p67 

    Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents...

  • Novel oral antiplatelets for acute coronary syndrome. Wright, Paul; Antoniou, Sotiris // British Journal of Cardiac Nursing;Apr2013, Vol. 8 Issue 4, p180 

    The thienopyridine clopidogrel, which irreversibly blocks the adenosine diphosphate (ADP) receptor P2Y12 on platelets, has become an essential component of therapy in patients with acute coronary syndromes. However, clopidogrel has drawbacks which has led to the development of newer more potent...

  • Acute coronary syndrome: potent oral antiplatelets. Wright, Paul; Antoniou, Sotiris // Nurse Prescribing;Aug2013, Vol. 11 Issue 8, p397 

    The thienopyridine clopidogrel, which irreversibly blocks the adenosine diphosphate (ADP) receptor P2Y12 on platelets, has become an essential component of therapy in patients with acute coronary syndromes. However, clopidogrel has drawbacks which has led to the development of newer more potent...

  • TRITON-TIMI 38: Prasugrel superior to clopidogrel for reducing cardiac risk in patients with ACS undergoing PCI.  // Formulary;Dec2007, Vol. 42 Issue 12, p666 

    The article examines on the improvement in Therapeutic Outcomes by Optimizing Platelet-Thombolysis in Myocardial Infarction 38 (TRITON-TIMI)38, a study which analyzed the efficacy of Prasugrel, an antiplatelet agent. According to the author, TRITON-TIMI 38 had showed a favorable result for the...

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Postgraduate Medical Journal;May2015, Vol. 91 Issue 1075, p284 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics